February 27th, 2009, by Digital Davo | research foundation
The National Rosacea Society have just announced their 2009 research grants. Four studies have been chosen, totally almost $90,000. Quite a buzz for me to see that a study in Australia has made the grade. Dr. Richard Gallo, who has received a lot of press coverage from the research on the role of cathelicidins, and …
February 25th, 2009, by Digital Davo | patents, topicals
My regular patent trolling has unearthed something potentially interesting. The anti-nausea drug Tropisetron is patented by Galderma as a treatment for inflammatory skin conditions including rosacea. Tropisetron is officially known as a 5-HT3 receptor antagonist or a serotonin antagonist. Serotonin (5-HT) is found widely distributed throughout the gut and the central nervous system ADMINISTRATION OF TROPISETRON FOR TREATING INFLAMMATORY SKIN …
February 23rd, 2009, by Digital Davo | seborrheic dermatitis
This paper summarises the current state of the art for seborrheic dermatitis – research and treatment options. The author mentions recent research that links seborrheic dermatitis with a spore known as Malassezia Globosa. He makes the point that azelaic …
February 20th, 2009, by Digital Davo | in the news, topicals
Following is an announcement from Rosacea Care. EXCITING NEWS We have just received word that four products that have been important to many rosacea sufferers will be available again later this spring. By arrangement with the originator of these products, the Rosacea Care Company will be manufacturing and distributing ZincO, Tinted ZincO, …
February 17th, 2009, by Digital Davo | in the news
L’Oréal has just posted its 2008 Annual Results. The results show that L’Oréal has had a good year, mostly because of the excellent performance of Galderma. It may come as a surprise to many to know that Galderma, the …
|
|
|
|
|
|